Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest TNF inhibitor Stories

2012-06-01 02:23:47

BRUSSELS, June 1, 2012 /PRNewswire/ -- UCB, a leading biopharmaceutical company, is sponsoring several data presentations for its immunology portfolio at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Berlin, Germany, June 6-9, 2012. "We are pleased to show our continued commitment to improving the lives of those living with autoimmune diseases," said Professor Dr. Iris Loew-Friedrich, Chief Medical Officer and Executive Vice President, UCB. "The...

2012-05-28 18:20:14

ABBOTT PARK, Ill., May 29, 2012 /PRNewswire/ -- Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA® (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012. The presentations include two of the longest open-label extension studies in rheumatoid arthritis (RA), featuring long-term data for disease activity and radiographic inhibition. Data will also be presented on...

2012-05-22 10:24:09

LEXINGTON, Mass., May 22, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company was awarded U.S. Patent 8,182,818, entitled "Methods of Using Anti-TNF Antibodies for Treating Radiation Damage to the Digestive Tract." This patent provides broad coverage for using topically administered anti-TNF antibodies to treat radiation induced damage to the...

2012-05-22 06:25:30

SAN DIEGO, May 22, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the thirteen abstracts relating to its proprietary diagnostic platform presented at Digestive Disease Week (DDW) 2012. The abstracts (see full list below) highlight Prometheus's innovative technologies aimed at helping healthcare providers personalize patient care with the goal of ultimately helping to improve patient outcomes. Topics span across a wide...

2012-05-21 10:23:23

SAN DIEGO, May 21, 2012 /PRNewswire/ -- New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI® (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents. Investigators presented data from the Janssen Research & Development, LLC, (Janssen)-sponsored Phase 3 study at...

2012-05-01 11:40:28

High-dose steroids found to significantly increase infection risk Children with juvenile idiopathic arthritis (JIA) have higher rates of hospitalized bacterial infection than children without JIA according to an observational study appearing in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR). The findings show that the risk of infection among JIA patients was significantly increased with use of high-dose...

2012-04-23 20:20:01

Tokyo, Apr 23, 2012 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) that the condition for approval of Humira(R) pre-filled syringe 40 mg/0.8 mL for subcutaneous injection (adalimumab [genetical recombination]), a fully human anti-TNF-alpha monoclonal antibody, has been lifted in terms of a drug use results survey (all-case surveillance) for plaque psoriasis and...

2012-04-18 10:36:05

A large-scale study of medical claims data shows that introducing sophisticated biologic therapies early in the course of treatment for Crohn's disease improves response to medication and reduces the need for surgery. There is no known cure for Crohn's disease, and traditional treatment is focused on a "step-up" strategy of managing inflammatory symptoms, starting with simpler and less costly oral medications such as aminosalicylates (5-ASAs) and corticosteroids, and escalating through a...

2012-03-19 06:24:29

LEXINGTON, Mass., March 19, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease. Avaxia Biologics has been awarded a Phase II Small Business Innovation Research (SBIR) grant...

2012-02-22 06:00:00

BRUSSELS, Feb. 22, 2012 /PRNewswire/ -- UCB today announced the start of C-EARLY(TM) - a phase III study that will evaluate the efficacy and safety of Cimzia® (certolizumab pegol) in combination with methotrexate (MTX) for inducing and sustaining clinical response in adults with early, progressive, active, moderate to severe rheumatoid arthritis (RA), who have not previously been treated with disease-modifying antirheumatic drugs (DMARDs). The study also aims to assess whether the...